1. Executive Summary
2. Global Anti diabetic Biosimilars Market Introduction
2.1. Global Anti diabetic Biosimilars Market– Taxonomy
2.2. Global Anti diabetic Biosimilars Market–Definitions
2.2.1. Drug Class
2.2.2. Disease Type
2.2.3. Distribution Channel
3. Global Anti diabetic Biosimilars Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Anti diabetic Biosimilars Market Dynamic Factors – Impact Analysis
3.6. Global Anti diabetic Biosimilars Market– Competition Landscape
3.7. Epidemiology
4. Global Anti diabetic Biosimilars MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market OpportunityAnalysis
5. Global Anti diabetic Biosimilars Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1. Insulin
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Biguanides
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Sulfonyl Ureas
5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Thiazolidinediones
5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors
5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. α-glucosidase Inhibitos
5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. GLP-1 Agonists
5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Others
5.8.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
6. Global Anti diabetic Biosimilars Market Forecast, By Disease Type, 2013 – 2017 and Forecast, 2017 – 2024
6.1. Type-I Diabetes
6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Type-II Diabetes
6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Anti diabetic Biosimilars Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Anti diabetic Biosimilars Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024
9. North America Anti diabetic Biosimilars Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Insulin
9.1.2. Biguanides
9.1.3. Sulfonyl Ureas
9.1.4. Thiazolidinediones
9.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors
9.1.6. α-glucosidase Inhibitos
9.1.7. GLP-1 Agonists
9.1.8. Others
9.2. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Type-I Diabetes
9.2.2. Type-II Diabetes
9.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024
9.6. North America Anti diabetic Biosimilars Market Dynamics – Trends
10. Europe Anti diabetic Biosimilars Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
10.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Insulin
10.1.2. Biguanides
10.1.3. Sulfonyl Ureas
10.1.4. Thiazolidinediones
10.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors
10.1.6. α-glucosidase Inhibitos
10.1.7. GLP-1 Agonists
10.1.8. Others
10.2. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Type-I Diabetes
10.2.2. Type-II Diabetes
10.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024
10.6. Europe Anti diabetic Biosimilars Market Dynamics – Trends
11. Asia-Pacific Anti diabetic Biosimilars Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
11.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Insulin
11.1.2. Biguanides
11.1.3. Sulfonyl Ureas
11.1.4. Thiazolidinediones
11.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors
11.1.6. α-glucosidase Inhibitos
11.1.7. GLP-1 Agonists
11.1.8. Others
11.2. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Type-I Diabetes
11.2.2. Type-II Diabetes
11.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024
11.6. Asia-Pacific Anti diabetic Biosimilars Market Dynamics – Trends
12. Latin America Anti diabetic Biosimilars Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
12.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Insulin
12.1.2. Biguanides
12.1.3. Sulfonyl Ureas
12.1.4. Thiazolidinediones
12.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors
12.1.6. α-glucosidase Inhibitos
12.1.7. GLP-1 Agonists
12.1.8. Others
12.2. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Type-I Diabetes
12.2.2. Type-II Diabetes
12.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024
12.6. Latin America Anti diabetic Biosimilars Market Dynamics – Trends
13. Middle East and Africa Anti diabetic Biosimilars Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
13.1. Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
13.1.1. Insulin
13.1.2. Biguanides
13.1.3. Sulfonyl Ureas
13.1.4. Thiazolidinediones
13.1.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors
13.1.6. α-glucosidase Inhibitos
13.1.7. GLP-1 Agonists
13.1.8. Others
13.2. Disease Type Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Type-I Diabetes
13.2.2. Type-II Diabetes
13.3. Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Anti diabetic Biosimilars Market- Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2018 – 2024
13.6. MEA Anti diabetic Biosimilars Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Biocon (India)
14.2.2. Merck Sharp & Dohme Corporation (U.S.)
14.2.3. Boehringer Ingelheim GmbH (Germany)
14.2.4. Eli Lilly & Co. (U.S.)
14.2.5. Sanofi-aventis U.S. LLC (U.S.)
14.2.6. Samsung Bioepis (Samsung BioLogics) (South Korea)
14.2.7. Mylan N.V. (U.S.)
14.2.8. Wockhardt (India)
15. Research Methodology
16. Key Assumptions and Acronyms